Half of Trigeminal Neuralgia Cases Are Misdiagnosed. A Small Study Points to an Unlikely Alternative to end pain regardless of the cause.

Most people with this condition can tell you how many teeth they lost before anyone got it right.

Two. Three. Sometimes an entire quadrant. Root canals on healthy molars. Extractions that changed nothing, because the problem was never in the tooth. It was in a nerve behind it, and the dentist had no way of knowing that from an x-ray.

This is not a rare failure. Studies in Dutch general practice found trigeminal neuralgia is misdiagnosed in up to 48% of cases. Roughly half. And because the pain sits in the upper and lower jaw, the first person most patients see is a dentist, which is exactly how irreversible procedures end up being performed on teeth that were never the problem.

Management of trigeminal neuralgia, a multi-centre case study in general practice, 2023.

By the time somebody finally says the words trigeminal neuralgia, most people have been in pain for a year or more, have been quietly treated as though they were exaggerating, and have lost teeth they will not get back.

An Indian integrative medicine company called Biogetica sells a protocol for this condition, and it is the subject of the study below. Here is the number it reports, followed immediately by what is wrong with it.

In 2022, a group of physicians published a study in the International Journal of Research in Ayurvedic Pharmacy. It examined a combination of Cronisol-D, OM 13 TN Formula and Neuralease. It reported that 68% of trigeminal neuralgia patients experienced relief, without the side effects associated with the standard drugs.

Sixty-eight percent means thirty-two percent did not.

Nearly one in three people in that study took the protocol and it did not do for them what it did for the others. That figure belongs beside the headline rather than in a footnote. Anyone already let down by three treatments is entitled to the failure rate before the price.

First, What This Condition Actually Is

The trigeminal nerve is the fifth cranial nerve. It carries sensation from your face, and it splits into three branches: one above the eye, one across the cheek and upper jaw, and one along the lower jaw.

When it misfires, the result is a sudden electric stab down one side of the face. Seconds to minutes. Triggered by nothing dramatic at all: chewing, talking, brushing your teeth, a cold draught through a window.

It is commonly called the suicide disease. That name is not marketing language invented by supplement companies. It is what clinicians have called it for decades, and the reason is documented: people living with trigeminal neuralgia carry a measurably higher risk of suicide than the general population.

Pain scales are a blunt instrument, but patients who have had both routinely rate a trigeminal attack above childbirth and above kidney stones. The attacks arrive without warning, several times an hour in a bad week, and there is nothing to do but wait out the twenty seconds. What breaks people is rarely a single attack. It is the arithmetic of a decade of them, plus the fact that nothing shows on a scan and almost nobody around them believes it is that bad.

Anyone reading this while in that place should know two things. There are treatments that work, several of them, and they are set out below. And if the thought of ending it has crossed your mind, that is a documented feature of this condition and not a personal failing. Please tell your doctor that part too, not just the pain score.

It is not common. UK primary care records covering 6.8 million people identified 8,268 cases, an incidence of about 27 per 100,000 person-years. It affects women more often than men, and the incidence climbs steeply with age. In men over eighty it reaches 45 per 100,000.

Being uncommon is part of the problem. It is why so many clinicians see it once or twice in a career, and why it takes so long for anyone to name it.

What Conventional Treatment Offers, and What It Costs

Carbamazepine works, and if you are on it, keep taking it. It is the established first-line treatment and the only drug with a specific FDA indication for trigeminal neuralgia. Nothing on this page is a reason to stop a prescription, and you should not change one without speaking to your own neurologist.

What the literature also records is the cost of staying on it. Carbamazepine increases pain relief compared with placebo, and it increases adverse effects: drowsiness, dizziness, rash, ataxia, liver damage. In one study of patients on carbamazepine or oxcarbazepine, the most frequently reported problems were tiredness, memory problems, sleepiness, difficulty concentrating and unsteadiness.

Then there is the harder part. For many people the dose that worked last year does not work this year, and the choice becomes a higher dose with heavier side effects, or a procedure.

Opioids are the option patients most often ask for and the one specialists are most reluctant to give. Not only because of dependency and tolerance, though both are real, but because trigeminal neuralgia responds poorly to them. It is a nerve-firing problem rather than a tissue-damage problem, and opioids are built for the second. Patients frequently end up dependent on a drug that was never going to control this particular pain.

Gamma Knife radiosurgery focuses radiation on the nerve root to damage it enough that it stops transmitting. There is no incision and no general anaesthetic, which is why it appeals to older patients and to anyone unfit for surgery. The trade-offs are that relief typically takes weeks to months to arrive, a substantial share of patients see the pain return within a few years, and facial numbness is a common and sometimes permanent result. It is also expensive.

Microvascular decompression is the one that actually addresses a cause. In a large share of cases the trigger is a blood vessel resting against the nerve root. A surgeon opens behind the ear, lifts the vessel away and pads it. For the right patient the results are the best available anywhere: high rates of complete relief, often lasting a decade or longer, with the nerve left intact rather than deliberately damaged.

It is also brain surgery. General anaesthetic, a craniotomy near the brainstem, several days in hospital and weeks of recovery. The recognised risks include hearing loss on that side, facial weakness, leakage of spinal fluid and, rarely, stroke. It is offered mainly to younger and fitter patients for exactly that reason, and it is not a realistic option for a great many people who have this condition.

The Five Options, Side by Side

Swipe the table sideways to see every column

Costs vary widely by country and insurer. The success figures quoted for surgical and medical options use different endpoints and different populations, so they cannot be read as a like-for-like ranking. Anyone comparing them, this page included, should say so plainly.

Every one of these is a legitimate option and some people should take the surgical ones. Nothing here is an argument against an operation that works. But there is a large group sitting between the drug that has stopped working and the procedure they are not ready for, or not eligible for, and conventional medicine offers that group very little.

Every one of these is a legitimate medical option and some people should take them. Nothing here is an argument against surgery. But there is a large group of people sitting between the drug that has stopped working and the operation they are not ready for, and almost nobody is offering that group anything at all.

What The Study Found, and What It Does Not Prove

Here is the finding, stated once, plainly. A group of physicians reported that the combination of four Biogetica formulas improved the health rate of 68% of trigeminal neuralgia patients, without the side effects that come with the standard drug regimen.

A separate paper, published on ScienceDirect, reported that trigeminal neuralgia patients using natural remedies obtained an overall reduction of more than 60% in both pain intensity and attack frequency.

Both papers are linked and public. Read them before you decide anything.

The caveats matter as much as the number.

The 2022 paper was published in a specialist Ayurvedic pharmacy journal, not in a general medical journal, and it is not indexed in the same databases your neurologist searches. That does not make it false. It does mean it has not been through the same level of scrutiny as a large randomised trial, and you should weigh it accordingly.

It also examined the manufacturer's own protocol. Research funded by the company selling the product is common across the whole of medicine, pharmaceutical medicine included, but readers are entitled to know it up front.

And 68% is not everyone. Read it next to the honest numbers on the other side: surgical studies measure complete pain relief, medical studies typically count 50% pain reduction as a success. These are not the same measurement, and anyone comparing them directly, us included, should say so.

What the evidence supports is narrower than the marketing around it. There is a published report that this protocol helped a majority of the people studied, without the drowsiness, memory problems and liver monitoring that come with the standard drugs. That is a real thing. It is not a cure, and no honest reading of the paper makes it one.

Why the Misdiagnosis Problem Matters Less for This Option Than the Others

Facial pain has several distinct causes and they do not all respond to the same thing. A blood vessel pressing on the nerve root. Demyelination from multiple sclerosis. A tumour. Post-herpetic damage. Dental and sinus problems that mimic all of the above. And a sizeable group where every scan is clean and no cause is ever identified.

Most conventional options are gated on which of those you have. Microvascular decompression only helps if there is a vessel to move, and does nothing for pain driven by MS. Gamma Knife targets a nerve root. Dental work fixes nothing at all if the tooth was never the problem, which is precisely how so many patients lose healthy molars before anyone reaches the right diagnosis.

The Biogetica protocol is built differently. Cronisol-D, Neuralease and the TN Formula are aimed at nerve support and inflammatory pathways rather than at a specific structural cause. GABA to reduce neuronal excitability, lion's mane studied for nerve growth factor, Bacopa monnieri for nerve structure, willow bark and devil's claw on the inflammatory side.

That is a claim about scope, not about superiority. It means the protocol is not conditional on getting the structural diagnosis right first, which matters a great deal when up to half of cases are misdiagnosed and the average patient waits more than a year for a correct one. It does not mean it works better than surgery for someone who has a vessel that can be moved.

There is a second structural difference worth naming. Carbamazepine suppresses symptoms and has to be taken continuously for as long as it keeps working, which is why dose escalation is such a familiar story. The protocol is sold as a four month course rather than an indefinite prescription, because nerve support is not something that produces a result in days and is not designed as an every-day-forever intervention. Whether that holds for any individual is exactly what the study did not settle for the 32%.

What Is Actually in the Salvation Kit

Six products. Every ingredient and every milligram is published in full on the product page. No proprietary blend, no hidden quantities, nothing you cannot take to your own neurologist before you order.

Cronisol-D. The nutraceutical core. GABA at 15mg, the inhibitory neurotransmitter that reduces neuronal excitability. Lion's mane at 30mg. Cat's claw at 50mg, ginkgo biloba at 45mg, devil's claw at 45mg, aloe vera and black currant at 35mg each, willow bark at 35mg, California poppy and horsetail at 20mg, Hypericum at 20mg. Then L-tryptophan, leucine, L-methionine, phosphatidyl-L-serine, magnesium gluconate, vitamin B6 and B12.

Neuralease. The Ayurvedic tablet, built on Bacopa monnieri at 200mg with Pluchea lanceolata, liquorice, amla, haritaki, vetiver and others, traditionally used to support nerve structure and function.

TN Formula. Homeopathic. Aconite 30, Hypericum 200, Hekla Lava 30, Spigelia 30.

OM 13 Formula. Potentized bioenergetic impressions with no actual molecules of peripheral nerve endings and the trigeminal nerve.

Equilibrium and Equilife. The two additional formulas that distinguish the Salvation Kit from the smaller Freedom Kit.

Two of those four components are homeopathic, and that requires a plain statement. As the United States Federal Trade Commission requires of anyone selling homeopathy: there is insufficient scientific evidence that homeopathy works, and homeopathic claims rest on theories from the 1700s that are not accepted by most modern medical experts. That position and the study result both appear on this page. Readers can weigh them against each other.

The company's doctors ask patients to stay on the protocol for four months, which is why the kits are sized the way they are. Several ingredients target nerve support rather than pain blocking, and that is not a three-day effect.

There Is More Than One Kit, and the Cheapest One May Be Enough

The advertiser's site lists several protocols and the difference between them is not obvious from the names, so here it is in plain terms.

Freedom Kit. The four-product core: Cronisol-D, TN Formula, OM 13 and Neuralease. Sold in three lengths. 40 days at $98, 80 days at $176, 160 days at $294. This is where most people start.

Salvation Kit. The same four plus Equilibrium and Equilife. The doctor recommended four month supply runs $449.10, reduced from $499.

Deliverance Kit. Sits between the two. The four month supply is $386.10.

Liberation and Essentials Kits. Built around myelin sheath sarcodes, one of them with topical CBD, at $161 and $126. These target the protective sheath around the nerve rather than the pain signal.

Nobody should buy the biggest box simply because it sits at the top of the page. The consultation exists partly to work out which of these fits, and a doctor who moves a patient down to the $98 kit is doing the job properly. All of them carry the same 100% money back guarantee.

Six Things You Can Check Before You Spend Anything

No reader should trust a company because a page about it sounded candid. Here is what can be verified independently, before any money changes hands.

The research. Both studies are public and linked, as is the FTC position on homeopathy. Read all three and reach a different conclusion if the evidence takes you there.

The formulation. Six products, every component and every milligram published openly.

The practitioner. A consultation with one of the company's doctors, free, before purchase. The panel and their registrations are listed publicly.

The manufacturing. GMP and WHO registered facilities, registered appropriately as supplements, homeopathic attenuations or Ayurvedic herbs.

The refund. 100% money back. No questions, no hoops.

The failure rate. It is in the headline of this page. Compare that against the last five pages you read about this condition.

That is six things you can check for yourself. Most pages in this market give you none.

Why Nobody Should Call This a Cure

The most common question about protocols like this one is why the company will not simply say it works.

Its competitors do say it. Search the condition and the first page of results is thick with sites promising permanent elimination of the pain. Those pages convert better than cautious ones, which is precisely why so many of them exist.

The recipe is not complicated. Put the word cure at the top, drop the failure rate, omit the FTC position on homeopathy, and hope nobody reads too closely.

Readers of this page are better served knowing all three of those things.

There is also a plain medical fact underneath it. Trigeminal neuralgia has no cure. Not from this protocol. Not from carbamazepine, which manages it. Not reliably from Gamma Knife, which damages the nerve and sometimes buys years rather than a lifetime. Microvascular decompression comes closest for some people and still carries no guarantee.

What exists is management. Fewer attacks. Longer gaps. Less of your day organised around not triggering it. Anyone promising you more than that is either uninformed or counting on you being desperate enough not to check.

My Promise to You

What the advertiser commits to, in its own words. No claim to cure a condition that has no cure. The failure rate published alongside the success rate. Every formulation disclosed in full, to the milligram. Every cited study public and linked, including the regulator's position on the discipline that two of the four components belong to. A free consultation with a qualified doctor before purchase, and that doctor may decline to recommend it. 100% money back. Each of those is checkable before a card is entered.

That set of commitments is checkable, which is the only reason it is worth printing.

The only people who cannot make a promise like this are the ones who already know what is really in their bottle.

Questions People Ask Before Booking the Consultation

The Bottom Line

For someone reading this at two in the morning, there are realistically two paths.

The first is to keep reading the pages that promise to eliminate the pain permanently. Some are very well written. A few will take the money. None will do what they said, because what they said is not possible, and six months later the search starts again.

The second is to work on the part of this that is actually within reach. Fewer attacks. Longer gaps between them. Nerve support rather than nerve damage. Alongside whatever a neurologist has prescribed, never instead of it.

That is the whole of what this protocol offers. It is smaller than what the competition promises. It helped 68% of the people in one study and did not help the rest. It is also the only version of the claim that survives contact with the evidence.

The free consultation is the sensible first step. It costs nothing, and given how often this condition is misdiagnosed, that conversation has value whether or not anything is purchased.